Hepatitis B virus as a gene delivery vector activating foreign antigenic T cell response that abrogates viral expression in mouse models.
Chronic hepatitis B virus (HBV) infection is characterized by functionally impaired T cell responses. To ensure active immunotherapy, the immune response must be switched from exhausted T cells to functional effectors that can attain the liver and cure the viral infection. We thus designed a recombinant HBV (rHBV) containing a modified viral core gene that specifically delivers a foreign antigenic polyepitope to the liver. This recombinant virus could only be self-maintained in hepatocytes already infected by HBV through capsid complementation. A strong foreign epitope-specific T cell response was first primed in the periphery by way of DNA immunization in human leukocyte antigen (HLA)-A2/DR1 transgenic mice. After the hydrodynamic (hyd.) injection of rHBV, expression of the foreign antigenic polyepitope in hepatocytes attracted/reactivated a vigorous T cell response in situ. Most liver-infiltrating CD8(+) T cells proved to be functional effectors. Following DNA priming and hyd. injection, the rHBV-based expression of hepatitis B surface antigen (HBsAg) in mouse liver was almost completely inhibited without causing major liver injury. Studies in HBsAg/HLA-A2/DR1 transgenic mice further validated our approach.


CONCLUSIONS
For the first time, HBV was used as a gene delivery vector, which strongly triggered functional T cell response and subsequently controlled the viral expression in the liver of surrogate mouse models for HBV infection. It might represent an innovative and promising strategy of active immunotherapy during HBV persistent infection. This concept could even be more generally extended to other chronic viral diseases.
Deng
Qiang
Q
Laboratoire Pathogenèse des Virus de l'Hépatite B, Institut Pasteur, Paris, France.
Mancini-Bourgine
Maryline
M
Zhang
Xiaoming
X
Cumont
Marie-Christine
MC
Zhu
Ren
R
Lone
Yu-Chun
YC
Michel
Marie-Louise
ML
D000818:Animals; D000941:Antigens / Q000378:metabolism*; D004195:Disease Models, Animal; D000939:Epitopes / Q000235:genetics; D005260:Female; D015967:Gene Expression Regulation, Viral / Q000502:physiology*; D018014:Gene Transfer Techniques; D005822:Genetic Vectors / Q000235:genetics*; D015789:HLA-A2 Antigen / Q000235:genetics / Q000378:metabolism; D015798:HLA-DR1 Antigen / Q000235:genetics / Q000378:metabolism; D006514:Hepatitis B Surface Antigens / Q000235:genetics / Q000378:metabolism; D006515:Hepatitis B virus / Q000235:genetics* / Q000502:physiology; D019698:Hepatitis C, Chronic / Q000235:genetics / Q000276:immunology / Q000473:pathology; D016233:Immunotherapy, Active; D008099:Liver / Q000276:immunology / Q000473:pathology / Q000821:virology; D051379:Mice; D008822:Mice, Transgenic; D013601:T-Lymphocytes / Q000276:immunology* / Q000473:pathology; D014779:Virus Replication / Q000502:physiology
D000941:Antigens; D000939:Epitopes; D015789:HLA-A2 Antigen; D015798:HLA-DR1 Antigen; D006514:Hepatitis B Surface Antigens